Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study, Published online: 14 May 2018; doi:10.1038/s41416-018-0100-3
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyfrom Cancer via ola Kala on Inoreader https://ift.tt/2IGovRr
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου